ContraFect Corporation Prices $10 Million Public Offering of Common Stock to Develop Novel Infectious Disease Treatments

July 30, 2018

ContraFect Corporation (Nasdaq:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $2.00 per share. All shares in the offering are to be sold by ContraFect. The gross proceeds from the offering will be $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect. In addition, ContraFect has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.

The offering is expected to close on or about July 31, 2018, subject to customary closing conditions.

Piper Jaffray & Co. and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering. Chardan is acting as lead manager for the offering.

ContraFect has one candidate in Ph II trials and four additional candidates in discovery/preclinical testing. The company is focused on discovering and developing therapeutic proteins and antibodies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. These infections cause an estimated 700,000 deaths annually worldwide. Their lysin and monoclonal antibody platforms target conserved regions of bacteria or viruses (regions that are not prone to mutation).

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.